Get the Stockscreener App
1.10
4.76%
0.05
Lucid Diagnostics Inc stock is traded at $1.10, with a volume of 663.15K.
It is up +4.76% in the last 24 hours and down -1.79% over the past month.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
See More
Previous Close:
$1.05
Open:
$1.06
24h Volume:
663.15K
Relative Volume:
0.60
Market Cap:
$119.33M
Revenue:
$4.35M
Net Income/Loss:
$-45.53M
P/E Ratio:
-1.0185
EPS:
-1.08
Net Cash Flow:
$-44.79M
1W Performance:
+7.84%
1M Performance:
-1.79%
6M Performance:
-24.66%
1Y Performance:
+29.87%
1-Day Range:
$1.035
$1.10
1-Week Range:
$0.98
$1.10
52-Week Range:
$0.73
$1.80
Lucid Diagnostics Inc Stock (LUCD) Company Profile
Name
Lucid Diagnostics Inc
Sector
Industry
Phone
212 949 4319
Address
360 MADISON AVENUE, NEW YORK
Compare LUCD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LUCD
Lucid Diagnostics Inc
|
1.10 | 103.93M | 4.35M | -45.53M | -44.79M | -1.08 |
|
ABT
Abbott Laboratories
|
132.59 | 226.73B | 43.11B | 13.94B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
106.17 | 152.69B | 18.49B | 2.50B | 3.49B | 1.68 |
|
SYK
Stryker Corp
|
394.22 | 145.89B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
92.71 | 118.91B | 33.54B | 4.69B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
81.83 | 45.97B | 5.69B | 1.41B | 577.90M | 6.95 |
Lucid Diagnostics Inc Stock (LUCD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-27-21 | Initiated | Ascendiant Capital Markets | Buy |
| Nov-08-21 | Initiated | BTIG Research | Buy |
| Nov-08-21 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-08-21 | Initiated | Needham | Buy |
Lucid Diagnostics Inc Stock (LUCD) Latest News
Lucid Diagnostics Reports Q2 2025 Financial Results - MSN
Lucid nearing Medicare coverage for EsoGuard test, maintain at Buy: BTIG - MSN
Cantor Fitzgerald reiterates Overweight rating on Lucid Diagnostics stock - Investing.com
Cantor Fitzgerald reiterates Overweight rating on Lucid Diagnostics stock By Investing.com - Investing.com UK
Lucid Diagnostics Q2 2025 Earnings Miss: A Deep Dive Into the Market Impact and Investor Strategy - AInvest
Lucid Diagnostics Posts Earnings Miss; Market Reaction and Investor Caution Rise - AInvest
Lucid Diagnostics Q2 Earnings Misses, Drives Negative Market Sentiment - AInvest
PAVmed Reports Q2 2025 Financial Results: $13.3M Net Loss, $1.2M in Lucid Diagnostics Revenue - AInvest
Lucid Diagnostics Q2 2025 Earnings Call Transcript - AInvest
Lucid Diagnostics shares rise 2.04% intraday after securing capital to extend runway past key reimbursement milestones. - AInvest
Quant Funds Rotate Into Lucid Diagnostics Inc. StockMarket Weekly Review & Intraday High Probability Alerts - newsyoung.net
PAVmed Q2 2025 slides reveal dramatic cost reduction amid Lucid Diagnostics growth - Investing.com
Lucid Diagnostics Q2 2025 Earnings: Revenue Grows, Net Loss Widens - AInvest
Lucid Diagnostics: Strong Financial Performance and Strategic Advancements Support Buy Rating - AInvest
Lucid Diagnostics Misses Earnings Again: Mixed Market Impact Amid Sector Resilience - AInvest
Lucid Diagnostics Advances Towards Medicare Coverage - MSN
Lucid Diagnostics: Strong Financial Performance and Strategic Advancements Justify Buy Rating - TipRanks
Lucid Diagnostics Inc. (NASDAQ:LUCD) Q2 2025 Earnings Call Transcript - Insider Monkey
PAVmed Reports Q2 2025 Financial Results, Lucid Diagnostics Recognizes $1.2M in Revenue and Processes 2,756 Tests - AInvest
PAVmed Provides Business Update and Reports Second Quarter 2025 Financial Results - MarketScreener
PAVmed's EsoGuard Cancer Test Hits 2,756 Q2 Tests as Medicare Coverage Decision Nears - Stock Titan
Lucid Diagnostics Provides Business Update and Reports Second Quarter 2025 Financial Results - BioSpace
Lucid Diagnostics Q2 2025 Earnings: Revenue Up, Loss Widens Amid Ongoing Expenses - AInvest
Lucid Diagnostics Reports Q2 2025 Earnings - TipRanks
Lucid Diagnostics Maintains Buy Rating Amid Potential Medicare Coverage Expansion and Financial Stability - AInvest
Lucid Diagnostics Reports Q2 Earnings, Revenue Below Consensus, CEO Optimistic on Medicare Coverage - AInvest
Lucid Diagnostics (LUCD): Navigating Medicare Coverage Milestones and Commercial Expansion to Unlock Long-Term Value - AInvest
Lucid Diagnostics Q2 2025: Conflicting Insights on Medicare Coverage, Patient Strategy, and Claims Process - AInvest
Lucid Diagnostics at Canaccord Conference: Medicare Coverage in Focus By Investing.com - Investing.com Canada
Lucid Diagnostics: Needham Reiterates Buy Rating, Raises PT to $3 - AInvest
Lucid Diagnostics Inc. (LUCD) Reports Q2 Loss, Tops Revenue Estimates - sharewise.com
Lucid Diagnostics: Buy Rating Affirmed Amid Potential Medicare Coverage Expansion and Financial Resilience - TipRanks
Lucid Diagnostics reports Q2 non-GAAP EPS (10c), consensus (10c) - TipRanks
Transcript : PAVmed Inc., Lucid Diagnostics Inc., Q2 2025 Earnings Call, Aug 13, 2025 - MarketScreener
Earnings call transcript: Lucid Diagnostics Q2 2025 revenue up, stock dips - Investing.com
Earnings call transcript: Lucid Diagnostics highlights Q2 2025 growth and Medicare focus - Investing.com Canada
Lucid Diagnostics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Lucid Diagnostics Q2 2025 Earnings: Revenue Exceeds Expectations, EPS Beats Estimates, Cash Position Strengthens - AInvest
Lucid Diagnostics reports $1.2mln revenue, $30mln cash, extends runway past reimbursement milestones. - AInvest
Lucid Diagnostics Inc: Navigating Earnings Challenges and Strategic Growth in a Competitive Diagnostics Landscape - AInvest
Lucid Diagnostics earnings beat, revenue was in line with estimates By Investing.com - Investing.com Canada
Lucid Diagnostics Inc Q2 loss per share $0.08 - MarketScreener
Lucid Diagnostics Q2 revenue up 1000% YoY to $1.2mln, cash runway extended. - AInvest
LUCD Reports Results - Nasdaq
Lucid Diagnostics 2025 Q2 Earnings Losses Narrow as Net Income Improves 59.7% - AInvest
Lucid Diagnostics Inc. SEC 10-Q Report - TradingView
PAVmed's Q2 2025 Earnings: A Strategic Inflection Point in Healthcare Innovation and Financial Turnaround - AInvest
What To Expect From Lucid Diagnostics Inc (LUCD) Q2 2025 Earnings - Yahoo Finance
Lucid Diagnostics LUCD 2025Q2 Earnings Preview Downside Anticipated on Underwhelming Market Performance - AInvest
Why Lucid Diagnostics Inc. stock attracts strong analyst attentionDaily Growth Stock Pick Reports Show Bullish Signals - metal.it
Lucid Diagnostics to Participate in Upcoming Investor Conferences - Eastern Progress
Lucid Diagnostics Inc Stock (LUCD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Lucid Diagnostics Inc Stock (LUCD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Matheis Dennis | Director |
May 21 '25 |
Buy |
1.32 |
129,684 |
171,520 |
316,782 |
| Matheis Dennis | Director |
May 22 '25 |
Buy |
1.32 |
33,218 |
43,795 |
350,000 |
0.89%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):